An investor asked on the investor interaction platform: Hello, excuse me, is the production capacity of 5 million units invested by the company with raised funds planned to be completed in 2023? Is it necessary to apply for approval after completion? How long will it take? Where can we find the batch issuance and production capacity of the company in recent years?
Chengdu Kanghua Biological Products Co.Ltd(300841) (300841. SZ) said on the investor interaction platform on January 24 that after the production expansion project invested by the company with raised funds is completed and put into operation, it is expected that the production capacity of freeze-dried human rabies vaccine (human diploid cells) can be increased by 6 million doses / year. The project is currently under construction and can be put into operation only after it is completed and passed relevant verification. Please pay attention to the official website of the Central Inspection Institute for the issuance of product batches.
